ClinicalTrials.gg
Not yet recruitingNCT06037720Updated Sep 14, 2023

Diagnostic Accuracy Study of a Point-of-Care Test for Coagulation Function

An observational study in CoaguChek® XS System and Coagulation Function, sponsored by Hospital de Base. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-09-14.

Sponsored by Hospital de Base · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jan 2024, 2 years 10 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-crossover
Time perspective
Cross-sectional
Enrollment
50
Ages
18 Years and older
Sex
All
01

Study summary

Intraoperative coagulopathies in complex procedures are common. For the diagnosis and adequate therapy, laboratory tests are necessary, which can delay the patient's therapy. In this sense, the study aims to evaluate the point-of-care test device for patients undergoing surgeries with cardiopulmonary bypass.

Objective: To analyze the accuracy between the point-of-care diagnostic method and the laboratory test considered the gold standard for checking the INR.

Methodology: Cross-sectional study of diagnostic accuracy with simultaneous testing of the Coaguchek XS device and standard laboratory method in patients undergoing cardiopulmonary bypass to evaluate INR results.

Read the detailed description

Laboratory evaluation of blood clotting is widely used in perioperative medicine, either by conventional technique (prothrombin time - PT/INR, Activated Partial Thromboplastin Time - aPTT, fibrinogen dosage and platelet count) or by the Point of Care method (Thromboelastogram ) - notably in surgical procedures with the possibility of severe volume loss (cardiovascular, oncological, trauma, etc.).

The prothrombin time (PT) is a general assessment of the integrity of the extrinsic and common pathway of coagulation. It determines the time of formation of the fibrin clot. The INR/RNI (International Normalized Ratio) is calculated from the PT and is intended to establish valid comparisons regardless of the type of PT reagent (known as thromboplastin) used by different clinical laboratories. The INR is indicated for evaluating the integrity of the extrinsic (factor VII*) and common pathway (fibrinogen and factors II*, V and X*), and for monitoring the anticoagulant effect of an anti-vitamin K agent (warfarin), capable of inhibiting the synthesis of vitamin K dependent factors (II, VII, IX, X, proteins C and S).

Today, due to its safety, sensitivity and speed, the thromboelastogram is recommended as the method of choice for assessing hemostasis in a surgical setting. However, because it is still not widespread in many centers, mainly due to its high cost, many hospitals are limited to the use of traditional laboratory methods which, despite their undeniable reliability, require more time for their execution and release of results.

In cardiac surgery with cardiopulmonary bypass (CPB), the use of prime solution to fill the CPB circuit results in hemodilution of coagulation factors, with factor I (fibrinogen) being one of the most affected, but not the only one. Each abnormality detected requires a specific action. Thus, the activated clotting time (ACT) is normalized with the administration of protamine. Thrombocytopenia and/or platelet dysfunction, with platelet concentrate infusion. Abnormalities in clotting factors, with administration of the specific factor, eg fibrinogen, either by factor concentrate, cryoprecipitate or plasma. It is at this moment that a quick assessment of hemostasis, in a global and individualized way at the same time, is necessary.

More than a decade ago, devices appeared on the market designed to help patients using warfarin to maintain their anticoagulation within parameters established for each case, providing safety, speed and comfort. Using a reagent strip and a drop of blood, evaluating the INR has become as simple as evaluating capillary blood glucose for diabetic patients. In just a few seconds, INR assessment can show significant changes in the extrinsic coagulation pathway, an important step to help with rapid decision-making in surgical environments. The Coaguchek Device, validated and used for outpatient management of patients using Warfarin, presents valuable characteristics for this purpose (simplicity, speed, safety), also important in the context of intraoperative decision-making. There are few reports in the literature on the use of the Coaguchek device in surgery and on the reliability of the data obtained through its use.

To evaluate this correlation, the main objective of the present study is to evaluate the effectiveness of the portable INR meter in a surgical setting and comparing it with conventional laboratory methods. The proposal is a cross-sectional diagnostic study in patients scheduled electively to undergo cardiac surgery with cardiopulmonary bypass at Hospital de Base in the Federal District.

All patients will receive standard monitoring associated with hemodynamic monitoring with invasive blood pressure and central venous access. Balanced general inhalation anesthesia will be administered to all patients. Hemodynamic support with dobutamine, noradrenaline, nitroprusside, nitroglycerin, vasopressin, or milrinone will be offered according to perioperative needs. The same commercial brand of heparin and protamine will be used to all the patients.

Laboratory tests, including samples for the Coaguchek device strip, will be collected 10 minutes before heparin administration and 10 minutes after the end of the protamine infusion. The laboratory exams that will be collected are: arterial blood gases, venous blood gases, electrolytes, complete blood count, coagulogram (TAP, aPTT, INR) and fibrinogen.

The sample size was calculated for the limits of agreement by Bland and Altman (1986)1, according to the method developed by Lu et al. (2016).2 Based on previous studies3-5, we assumed a mean difference between the POC test and the laboratory test of 0.126 units with a standard deviation of 0.132. Furthermore, based on clinical criteria, we consider that an absolute difference greater than 0.5 units will be clinically relevant. In other words, the maximum difference (Δ) between the tests (so as not to change the clinical approach) would be up to ± 0.5 units; that is, (-Δ ,Δ) equals (-0.5,0.5). Assuming a 5% ɑ level and 95% confidence intervals around the Bland-Altman limits of agreement, 43 participants were needed to ensure a statistical power of 90% to detect agreement between the two methods. All calculations were performed using the Stata 16 program (StataCorp, Texas, United States). We decided to increase the sample to 50 patients for cases of loss to follow-up or failures in annotations.

02

Conditions studied

  • CoaguChek® XS System
  • Coagulation Function

Keywords

  • CoaguChek® XS System
  • International normalized ratio
  • Point-of-care testing
  • Cardiopulmonary bypass
03

In context

Lead sponsor

Hospital de Base is the lead sponsor of 25 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients scheduled electively to undergo cardiac surgery with cardiopulmonary bypass at Hospital de Base in the Federal District.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patients over 18 years old
  • admitted to the Hospital de Base of the Federal District for cardiac surgery, who volunteered to participate in the examination both by the traditional method of venous examination and by the use of the Coaguchek device and only after signing the TCLE.

Exclusion criteria

Exclusion Criteria:

  • patients who give up the research even after signing the TCLE will be excluded
  • patients who do not meet the aforementioned inclusion criteria
  • patients who refuse to participate in the study
  • patients with kidney, liver, hematological disease or any disease that affects coagulation
  • patients participating in other studies
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Observational model
Case-crossover
Time perspective
Cross-sectional
Enrollment
50 participants (estimated)
Patient registry
No

Interventions

  • DeviceCoaguchek testing

    Patients scheduled electively to undergo cardiac surgery with cardiopulmonary bypass at Hospital de Base in the Federal District.

06

What researchers measure

Primary outcomes

  1. Point-of-care diagnostic method

    To analyze the accuracy between the point-of-care diagnostic method and the laboratory test considered the gold standard for verifying the INR.

    Time frame: During surgery

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Khalaf-Adeli E, Alavi M, Alizadeh-Ghavidel A, Pourfathollah AA. Comparison of standard coagulation testing with thromboelastometry tests in cardiac surgery. J Cardiovasc Thorac Res. 2019;11(4):300-304. doi: 10.15171/jcvtr.2019.48. Epub 2019 Oct 13. PubMed 31824611 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2023; primary completion for Jan 2024, 4 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 7, 2023
First posted
Sep 14, 2023
StartEst.
Sep 2023
Primary completionEst.
Jan 2024
CompletionEst.
Jan 2024
Last update
Sep 14, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 14, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06037720
Lead sponsor
Hospital de Base
Responsible party
Fabricio Tavares Mendonca (MD, MSc, PhD, Hospital de Base) — Principal investigator
First posted
Sep 14, 2023
Start date
Sep 2023 (estimated)
Primary completion
Jan 2024 (estimated)
Completion
Jan 2024 (estimated)
Last update
Sep 14, 2023

Study contacts

Nadja Gloria C Graça, MD
Contact
nadjagcg@hotmail.com
556133151588

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion